Related Experiment Videos
Transrectal microwave hyperthermia for patients with benign prostatic hyperplasia
1Department of Urology, University of Patras School of Medicine, Rio Patras, Greece.
Summary
Transrectal microwave hyperthermia (TMH) offers significant symptom relief for benign prostatic hyperplasia (BPH) patients. This treatment improves urinary flow and reduces residual urine, providing a viable option for specific patient groups.
Area of Science:
- Urology
- Medical Devices
- Therapeutic Technologies
Background:
- Benign prostatic hyperplasia (BPH) is a common condition affecting aging men.
- Evaluating novel, minimally invasive treatments for BPH is crucial.
- Transrectal microwave hyperthermia (TMH) presents a potential therapeutic option.
Purpose of the Study:
- To assess the efficacy of transrectal microwave hyperthermia (TMH) in managing benign prostatic hyperplasia (BPH).
- To compare TMH outcomes against a sham treatment in BPH patients.
Main Methods:
- A randomized study involving 80 BPH patients receiving TMH and 20 receiving sham treatment.
- TMH involved 5-6 sessions of 1-hour duration, heating the prostate to 42-43.5°C.
- Sham treatment consisted of a single session at 37°C, with evaluations at 3 and 12 months.
Main Results:
- 75% of TMH-treated patients experienced improved obstructive symptoms.
- Significant improvements in urodynamic parameters, including increased maximum flow rate.
- Marked reduction in residual urine volume (P < 0.0001) and detrusor pressures.
Conclusions:
- TMH demonstrates efficacy in improving subjective and objective BPH symptoms.
- It is a suitable alternative for patients with indwelling catheters or high surgical risk.
- TMH is a valid therapeutic option, though not superior to surgical interventions.